EUCTR2010-021755-34-IT进行中（未招募）不适用
Phase II study on imatinib in combination with RAD001 in advanced chordoma - imatinib in combination with RAD001 in advanced chordoma
ISTITUTO NAZIONALE PER LA CURA TUMORI0 个研究点开始时间: 2010年9月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •diagnosis of chordoma
- •PDGFRB/PDGFB e mTOR (or S6 or 4BP1) expression
- •advanced disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •No prior, or ongoing other malignancy, except adequately treated basal cell or squamous cell, skin cancer, in situ cervical cancer or adequately treated cancer with eradicative intent.
- •Patients receiving chemotherapy, immunotherapy, radiation therapy or any other investigational agent within 4 weeks of the first dose of study drug. Imatinib in monotherapy is allowed
- •Patients with known history of hypersensitivity against imatinib or everolimus (or other rapamycin analogs), or to their excipients.
- •Patients receiving systemic treatment with immunosuppressive agent
研究者
相似试验
招募中
2 期
Phase II trial using imatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)ewly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)JPRN-UMIN000001226Japan Adult Leukemia Study Group66
进行中（未招募）
1 期
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 20.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10051066 Term: Gastrointestinal stromal tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-GBEuropean Organisation for Research and Treatment of Cancer76
进行中（未招募）
不适用
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 18.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-ESEuropean Organisation for Research and Treatment of Cancer240
招募中
2 期
A randomised phase II trial of imatinib alternating with;regorafenib compared to imatinib alone for the first line ;treatment of advanced gastrointestinal stromal tumour (GIST)GISTgastrointestinal stromal tumour10072990NL-OMON56311European Organisation for Research in Treatment of Cancer (EORTC)18
进行中（未招募）
1 期
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)EUCTR2015-001298-42-FREuropean Organisation for Research and Treatment of Cancer240